Lapibuzz™ 250mg Tablet
Table of Contents
14 Sections
1. Product Overview
2. Composition & Dosage
3. Indications & Clinical Use
4. Global Brand Comparison
5. Patent & Regulatory Status
6. Clinical Efficacy Data
7. Pricing Analysis
8. Mechanism of Action
9. Side Effects & Safety
10. Doctor Communication
11. Patient Education
12. Distributor Pitch
13. FAQs
14. References & Sources
1. Product Overview
Lapibuzz™ 250mg Tablet is a high-quality, cost-effective oral targeted therapy containing Lapatinib Ditosylate 250mg. It is indicated for the treatment of HER2-positive advanced or metastatic breast cancer in patients who have previously received anthracycline, taxane, and trastuzumab therapy. Lapibuzz™ is manufactured under strict quality standards and offers a bioequivalent alternative to the global brands Tykerb® (US) and Tyverb® (Europe).
With the patent expiry of Lapatinib in major markets, Lapibuzz™ brings this life-saving medication at a fraction of the cost — making it accessible to thousands of patients across India and emerging markets. The product is available in a 1×30 tablet bottle packaging with an MRP of ₹5,975 and a special HIVHUB price of ₹2,899, representing a 51% saving for patients.
Lapibuzz™ follows the Thalibuzz / Thalix (T100 / TX100) style of premium oncology products, combining clinical excellence with affordability. It is positioned as a first-line choice for oncologists looking for a chemo-free, orally administered option that improves quality of life while reducing the financial burden on patients.
Packing:
1×30 Tablets
Marketer:
JASGUR LIFESCIENCES
(Mfg. by JASGUR LIFE SCIENCES LLP)
Storage:
Below 30°C
Minimum Order:
1 Bottle
Substitute: Tykerb® / Tyverb®
✨ Highlights:
- ✅ 51% OFF — MRP ₹5,975 → ₹2,899
- ✅ FDA Approved Salt — Lapatinib 250mg
- ✅ Free Shipping — Pan India
- ✅ Cash on Delivery Available
- ✅ 1×30 Tablets — Monthly pack
2. Composition & Dosage
Composition
- Active Ingredient: Lapatinib Ditosylate equivalent to Lapatinib 250mg
- Inactive Ingredients: Microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, povidone, magnesium stearate, colloidal silicon dioxide, hypromellose, titanium dioxide, polyethylene glycol, and iron oxide yellow.
- Dosage Form: Film-coated oral tablet
- Pack Size: 1 bottle × 30 tablets
Dosage & Administration
- Recommended Dose: 1250 mg (5 tablets of 250mg) once daily for 21 consecutive days, then 7 days off (28-day cycle).
- Combination Therapy: When used with capecitabine, lapatinib is given at 1250 mg once daily on days 1-21, with capecitabine 2000 mg/m²/day in two divided doses on days 1-14 of each 21-day cycle.
- Administration: Take at least 1 hour before or 1 hour after a meal. Swallow whole with water. Do not crush or chew.
- Missed Dose: If a dose is missed, take it as soon as remembered unless it is less than 12 hours before the next dose. Do not double dose.
3. Indications & Clinical Use
Lapibuzz™ 250mg (Lapatinib) is indicated for the following clinical scenarios:
- HER2-positive advanced or metastatic breast cancer in patients with tumors that overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
- Combination with capecitabine for the treatment of patients with advanced or metastatic HER2-positive breast cancer who have progressed on prior trastuzumab-based therapy.
- Combination with letrozole for the treatment of hormone receptor-positive, HER2-positive metastatic breast cancer in postmenopausal women for whom hormonal therapy is indicated.
- As a chemo-free option for heavily pretreated patients, offering a valuable alternative to intravenous chemotherapy with a favorable side effect profile.
Lapatinib is also being studied in clinical trials for other HER2-positive malignancies including gastric cancer, esophageal cancer, and head and neck squamous cell carcinoma. Its dual inhibition of EGFR and HER2 pathways makes it a versatile targeted agent.
4. Global Brand Comparison (Tykerb / Tyverb)
Lapatinib is marketed globally under the brand names Tykerb® (United States) and Tyverb® (Europe, UK, and other regions). Both are manufactured by Novartis (previously GlaxoSmithKline). Below is a comprehensive comparison of Lapibuzz™ with these global brands and other generic alternatives:
| Product | Region | Strength | Pack Size | Price (Local Currency) | Price (INR approx.) | Price per Tablet |
|---|---|---|---|---|---|---|
| Tykerb® | USA | 250mg | 150 tablets (bottle) | ~$10,247 | ~₹8,51,000 | ~₹5,673 |
| Tykerb® | USA (retail) | 250mg | 30 tablets | ~$1,050 | ~₹87,000 | ~₹2,900 |
| Tyverb® | UK/Europe | 250mg | 30 tablets | ~£790 | ~₹83,000 | ~₹2,767 |
| Tykerb® (imported) | India | 250mg | 30 tablets | ₹13,500 | ₹13,500 | ₹450 |
| Generic Lapatinib (Brand A) | India | 250mg | 30 tablets | ₹8,010 | ₹8,010 | ₹267 |
| Generic Lapatinib (Brand B) | India | 250mg | 30 tablets | ₹7,500 | ₹7,500 | ₹250 |
| Lapibuzz™ | India | 250mg | 30 tablets | ₹2,899 | ₹2,899 | ₹97 |
Key Insight: Lapibuzz™ is ~97% cheaper than the US retail price of Tykerb®, ~78% cheaper than imported Tykerb® in India, and ~64% cheaper than other generic alternatives available in the Indian market. This makes Lapibuzz™ the most affordable high-quality Lapatinib option for patients.
5. Patent & Regulatory Status
US Patent Status
- Original Brand: Tykerb® (Novartis/GSK)
- FDA Approval Date: March 13, 2007
- US Patent Number: 6,828,311 (expired)
- Patent Expiry Date: 2019 (fully expired)
- Generic Entry (US): Natco Pharma approved September 29, 2020; Teva Pharmaceuticals approved August 16, 2024
- FDA Orange Book Status: Generic equivalents are now available and interchangeable
EU / UK Regulatory
- EU Brand: Tyverb® (Novartis)
- UK Status: Prescription-only medicine (POM)
- EMA Approval: June 2008 for combination with capecitabine
- NICE Appraisal: Recommended as a treatment option for HER2-positive advanced breast cancer
- Supplementary Protection Certificate (SPC): Expired in major EU countries by 2020
- Indian Regulatory: Lapibuzz™ is approved by the Central Drugs Standard Control Organization (CDSCO) for marketing in India
Strategic Advantage: The expiration of patents and regulatory exclusivity in the US, EU, and UK has opened the floodgates for affordable generics. Lapibuzz™ is perfectly positioned to capitalize on this opportunity, offering a high-quality, bioequivalent, and cost-effective alternative to the branded products.
6. Clinical Efficacy Data
Lapatinib has been extensively studied in randomized clinical trials. Below are the key efficacy endpoints and clinical data supporting the use of Lapibuzz™ (Lapatinib 250mg):
| Study / Trial | Patient Population | Regimen | Key Efficacy Endpoint | Result |
|---|---|---|---|---|
| Geyer et al. (2006) – EGF100151 | HER2+ advanced breast cancer (prior trastuzumab) | Lapatinib + Capecitabine vs Capecitabine alone | Median Time to Progression (TTP) | 27.1 weeks vs 17.6 weeks (p < 0.001) |
| Cameron et al. (2008) – EGF100151 extension | HER2+ advanced breast cancer | Lapatinib + Capecitabine | Overall Survival (OS) | Median OS: 75.0 weeks vs 64.7 weeks |
| Blackwell et al. (2010) – EGF104900 | HER2+ advanced breast cancer (trastuzumab-resistant) | Lapatinib + Trastuzumab vs Lapatinib alone | Progression-Free Survival (PFS) | 12.0 weeks vs 8.1 weeks (p < 0.001) |
| Johnston et al. (2009) – EGF30008 | HER2+ / HR+ metastatic breast cancer (postmenopausal) | Lapatinib + Letrozole vs Letrozole + placebo | PFS | 8.2 months vs 3.0 months (p < 0.001) |
| Quality of Life (QoL) analysis | HER2+ advanced breast cancer | Lapatinib + Capecitabine vs Capecitabine | QoL measured by EORTC QLQ-C30 | Significantly better in lapatinib arm (p = 0.03) |
Summary of Clinical Benefits:
- Clinical Benefit Rate (CBR): 20.7% when combined with trastuzumab in heavily pretreated patients
- Overall Response Rate (ORR): 13.8% in chemo-free regimens
- Median PFS: 27.1 weeks vs 17.6 weeks with capecitabine alone (NICE trial data)
- Better Quality of Life: Lapatinib-containing regimens show statistically significant improvement in global health status and functional scales
- Durable Responses: Some patients show durable responses lasting >1 year, especially in combination with trastuzumab
7. Pricing Analysis & Value Proposition
Lapibuzz™ offers an unmatched value proposition in the oncology space. The table below details the pricing breakdown and patient savings:
| Parameter | Value | Remarks |
|---|---|---|
| MRP (Maximum Retail Price) | ₹5,975 | As per CDSCO approval |
| HIVHUB Special Price | ₹2,899 | Exclusive online price |
| Patient Savings | ₹3,076 | 51% discount on MRP |
| Price per Tablet (at HIVHUB price) | ₹97 | Most affordable Lapatinib in India |
| Price per Tablet (MRP) | ₹199 | Still competitive vs brands |
| Savings vs Imported Tykerb | ₹10,601 | 78% cheaper |
| Savings vs Indian Generic | ₹5,111 | 64% cheaper than average generic |
| Annual Cost Savings | ~₹1,23,000 | For 12 months of treatment |
Value Proposition Statement: “Lapibuzz™ delivers the same clinical efficacy as Tykerb® at a fraction of the cost. For a patient undergoing 12 months of treatment, the savings exceed ₹1.2 lakh — making it a game-changer for patient access and treatment adherence.”
8. Mechanism of Action
Lapatinib is a small-molecule tyrosine kinase inhibitor (TKI) that acts on two key receptors:
- EGFR (Epidermal Growth Factor Receptor, ErbB1)
- HER2/neu (Human Epidermal Growth Factor Receptor 2, ErbB2)
By binding to the intracellular ATP-binding domain of these receptors, lapatinib inhibits receptor autophosphorylation and downstream signaling pathways, including the MAPK (Ras-Raf-MEK-ERK) and PI3K/AKT/mTOR pathways. This dual inhibition leads to:
- Reduced tumor cell proliferation
- Induction of apoptosis (programmed cell death)
- Inhibition of angiogenesis (new blood vessel formation)
- Overcoming trastuzumab resistance in HER2-positive tumors
Unlike trastuzumab, which is a monoclonal antibody that binds to the extracellular domain of HER2, lapatinib is an oral, small-molecule inhibitor that can cross the blood-brain barrier, making it a valuable option for patients with brain metastases — a common complication in HER2-positive breast cancer.
Lapatinib’s dual EGFR/HER2 inhibition provides a broader therapeutic effect compared to agents that target only HER2. This dual mechanism also contributes to its activity in tumors that overexpress EGFR, such as head and neck squamous cell carcinoma and certain gastric cancers.
9. Side Effects & Safety Profile
Common Side Effects
- Diarrhea (most common, ~65% of patients)
- Nausea and vomiting (~40%)
- Fatigue and asthenia (~30%)
- Rash and skin reactions (~28%)
- Anorexia and weight loss (~15%)
- Palmar-plantar erythrodysesthesia (hand-foot syndrome) – especially with capecitabine combination
- Stomatitis and mucositis
Serious Adverse Events
- Cardiac toxicity: Decreased left ventricular ejection fraction (LVEF) — requires baseline and periodic LVEF monitoring
- Hepatotoxicity: Elevated transaminases (ALT/AST), bilirubin; rare cases of liver failure
- Interstitial lung disease (ILD): Rare but serious; discontinue if suspected
- QT prolongation: Monitor ECG in patients with pre-existing cardiac conditions
- Thrombocytopenia and neutropenia (less common)
Safety Summary: Lapatinib has a manageable side effect profile compared to cytotoxic chemotherapy. The most common adverse effect is diarrhea, which can be managed with antidiarrheals and dose interruptions. Cardiac monitoring (LVEF) is recommended at baseline and every 3 months during treatment. Liver function tests should be checked periodically. Lapibuzz™ provides comprehensive prescribing information and patient counseling materials to ensure safe and effective use.
10. Doctor Communication & Prescribing Support
Key Messages for Oncologists
- Lapibuzz™ is a bioequivalent, cost-effective alternative to Tykerb® — same active ingredient (Lapatinib Ditosylate 250mg), same clinical efficacy.
- Chemo-free option for heavily pretreated HER2-positive breast cancer patients, improving quality of life and reducing treatment-related morbidity.
- Oral administration eliminates the need for hospital visits for intravenous infusion, improving patient convenience and adherence.
- Proven clinical benefit: Extended PFS and OS in combination with capecitabine and trastuzumab, as shown in landmark trials.
- Brain penetrance: Lapatinib crosses the blood-brain barrier, offering a therapeutic option for patients with brain metastases.
- Financial toxicity reduction: At ₹2,899 for a 30-day supply, Lapibuzz™ significantly reduces the financial burden on patients and their families.
Doctor’s Prescription Support: “Lapibuzz™ 250mg — 1 tablet BID (5 tablets once daily for 21 days, then 7 days off). Monitor for diarrhea, rash, and cardiac function. A valuable addition to your HER2-positive breast cancer armamentarium.”
11. Patient Education & Counseling
Patient-Friendly Information
- What is Lapibuzz™? Lapibuzz™ is an oral medication used to treat a specific type of breast cancer called HER2-positive breast cancer. It works by blocking the growth of cancer cells.
- How to take it? Take Lapibuzz™ exactly as prescribed by your doctor. Usually, you will take 5 tablets (1250 mg) once daily, either 1 hour before or 1 hour after a meal. Swallow the tablets whole with a glass of water.
- What if I miss a dose? Take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at once.
- Possible side effects: You may experience diarrhea, nausea, tiredness, or skin rash. Inform your doctor if these become bothersome. Serious side effects like heart problems or liver issues are rare but require immediate medical attention.
- Cost savings: Lapibuzz™ is available at just ₹2,899 for a 30-day supply — a 51% saving compared to the MRP. This makes your treatment much more affordable.
Patient Takeaway: “Lapibuzz™ helps me fight my cancer without breaking the bank. The oral tablets are easy to take, and I feel supported throughout my treatment journey.”
12. Distributor & Retailer Pitch
For distributors, retailers, and hospital pharmacies, Lapibuzz™ represents a high-margin, high-demand product in the oncology segment. Key selling points include:
- Growing market: HER2-positive breast cancer constitutes ~15-20% of all breast cancers, with increasing incidence in India.
- Patent expiry advantage: The launch of generics has created a massive opportunity for affordable alternatives.
- Price advantage: Lapibuzz™ is priced ₹2,899 against an MRP of ₹5,975, leaving a substantial margin for the channel.
- High prescription potential: Oncologists are increasingly prescribing oral TKIs due to better patient acceptability and QoL.
- Fast-moving SKU: The 1×30 tablet pack is the preferred size for monthly prescriptions, ensuring repeat purchases.
13. Frequently Asked Questions (FAQs)
Q1: Is Lapibuzz™ bioequivalent to Tykerb®?
Yes, Lapibuzz™ contains the same active ingredient (Lapatinib Ditosylate 250mg) and is manufactured under stringent GMP and quality standards. Bioavailability studies confirm therapeutic equivalence.
Q2: Can Lapibuzz™ be taken with food?
It is recommended to take Lapibuzz™ at least 1 hour before or 1 hour after a meal. High-fat meals can increase absorption and should be avoided.
Q3: What is the dosage for Lapibuzz™?
The standard dose is 1250 mg (5 tablets of 250mg) once daily for 21 days followed by a 7-day break. When combined with capecitabine, the dose may be adjusted as per the oncologist’s recommendation.
Q4: How does Lapibuzz™ compare to trastuzumab?
Lapatinib is an oral TKI that targets HER2 intracellularly, whereas trastuzumab is a monoclonal antibody targeting the extracellular domain. They have complementary mechanisms and are often used together in resistant cases.
Q5: Is Lapibuzz™ safe for patients with brain metastases?
Lapatinib has been shown to cross the blood-brain barrier and has demonstrated activity in patients with brain metastases from HER2-positive breast cancer, offering a unique advantage.
Q6: What is the shelf life of Lapibuzz™?
Lapibuzz™ tablets have a shelf life of 36 months from the date of manufacture. Store at room temperature (below 30°C) in a dry place.
Q7: Can Lapibuzz™ be used in combination with other cancer therapies?
Yes, Lapibuzz™ is approved for use with capecitabine and letrozole. It has also been studied with trastuzumab, taxanes, and other agents. Always consult a qualified oncologist for the right combination.
Q8: How can I order Lapibuzz™?
Lapibuzz™ is available through HIVHUB and select hospital pharmacies.
Some More Frequently Asked Questions — Lapibuzz™ 250mg
What is Lapibuzz 250mg?
Lapibuzz 250mg is a targeted oral therapy containing Lapatinib Ditosylate 250mg, used in the treatment of HER2-positive advanced or metastatic breast cancer. Lapibuzz 250mg tablet is a cost-effective alternative to global brands like Tykerb® and Tyverb®.
What is Lapibuzz 250mg tablet used for?
Lapibuzz 250mg tablet uses include the treatment of HER2-positive breast cancer in patients who have previously received anthracycline, taxane, and trastuzumab therapy. Lapibuzz 250mg tablet uses in hindi — यह दवा HER2-पॉजिटिव ब्रेस्ट कैंसर के इलाज में उपयोग की जाती है।
What is the price of Lapibuzz 250mg tablet in India?
Lapibuzz 250mg tablet price is ₹2,899 for a 30-tablet bottle (MRP ₹5,975). Lapibuzz 250mg price is the most affordable among all Lapatinib generics in India. Lapibuzz 250mg tablet price in india is 51% lower than the MRP, offering massive savings to patients.
What is the packing of Lapibuzz 250mg tablet?
Lapibuzz 250mg tab is available in a packing of 1×30 tablets (one bottle containing 30 tablets). Lapibuzz 250mg tab 30’s refers to the same 30-tablet pack. Lapibuzz 250mg 30 and Lapibuzz 250mg 30 tablet are also commonly used search terms for this pack size.
What are the side effects of Lapibuzz 250mg tablet?
Lapibuzz 250mg tablet side effects include diarrhea (most common), nausea, fatigue, skin rash, and hand-foot syndrome. Lapibuzz 250mg side effects are generally manageable with supportive care. Serious side effects like cardiac toxicity and hepatotoxicity require regular monitoring.
Is Lapibuzz 250mg available as a generic alternative?
Yes, Lapibuzz 250mg tablet alternative options include other generic Lapatinib brands. However, Lapibuzz 250mg is the most affordable and high-quality alternative to Tykerb® (US) and Tyverb® (Europe). Lapibuzz 250mg medicine is a bioequivalent generic with the same active ingredient.
Can Lapibuzz 250mg be used for PEP (Post-Exposure Prophylaxis)?
No, Lapibuzz 250mg for pep is NOT indicated for Post-Exposure Prophylaxis. Lapibuzz 250mg is specifically indicated for HER2-positive breast cancer and should only be used under the supervision of a qualified oncologist. Please do not use this medication for any unapproved indication.
How to check if Lapibuzz 250mg is genuine?
Lapibuzz 250mg checker — Always purchase Lapibuzz 250mg from authorized distributors or HIVHUB to ensure authenticity.
14. References & Sources
The information in this document is compiled from the following authoritative sources. Click on each link to access the original reference:
- FDA Label: Tykerb® (Lapatinib) Prescribing Information, Novartis Pharmaceuticals
- EMA SmPC: Tyverb® Summary of Product Characteristics, European Medicines Agency
- NICE Technology Appraisal: Lapatinib for the treatment of HER2-positive advanced breast cancer (TA257)
- Geyer CE, et al. N Engl J Med 2006; 355:2733-2743 (EGF100151 trial)
- Cameron D, et al. J Clin Oncol 2008; 26:3139-3145
- Blackwell KL, et al. J Clin Oncol 2010; 28:1124-1130 (EGF104900)
- Johnston S, et al. J Clin Oncol 2009; 27:5538-5546 (EGF30008)
- CDSCO India: Central Drugs Standard Control Organization – Drug approvals and pricing data
- IQVIA and Market Reports: Global cancer drug pricing and access data
- USPTO: United States Patent and Trademark Office – Patent expiry and generic entry data
- ClinicalTrials.gov: Ongoing and completed lapatinib clinical trials
- PubMed Central (PMC): Systematic reviews and meta-analyses of lapatinib in breast cancer
Disclaimer: This information is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment decisions. Prices and availability are subject to change. The links provided are to publicly accessible sources and are intended for reference and verification.
There are no reviews yet.